Breaking News Instant updates and real-time market news.

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

, RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

11:44
11/21/18
11/21
11:44
11/21/18
11:44

Aquestive selloff on generic Suboxone decision overdone, says RBC Capital

RBC Capital analyst Randall Stanicky attributes the added pressure on Aquestive Therapeutics (AQST) shares to yesterday's decision to lift the preliminary injunction on Dr. Reddy's (RDY) launching a generic version of Suboxone. He notes this will impact the milestones that Aquestive receives from Indivior, with the remaining milestones now unlikely. However, he notes that Suboxone in total comprises about $3 per share in value in his model, which is meaningfully less than the two-day selloff of $7 in the stock, which makes the pullback "meaningfully overdone" in his view. Stanicky has an Outperform rating on Aquestive shares with a $24 price target.

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

  • 29

    Jan

AQST Aquestive Therapeutics
$9.60

-3.57 (-27.11%)

08/31/18
BMOC
08/31/18
NO CHANGE
Target $26
BMOC
Outperform
Aquestive Therapeutics' Sympazan approval is major achievement, says BMO Capital
BMO Capital analyst Gary Nachman kept his Outperform rating and $26 price target on Aquestive Therapeutics, saying the tentative approval that it received today for Sympazan to treat Lennox-Gastaut Syndrome is an "important achievement". The analyst notes the decision is validating the company's PharmFilm technology which is "helping set the stage for its commercial build-out in CNS and anticipation for the bigger Libervant opportunity in refractory seizures."
09/12/18
WEDB
09/12/18
INITIATION
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
09/13/18
WEDB
09/13/18
INITIATION
Target $33
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Aquestive Therapeutics with an Outperform rating and $33 price target. The analyst considers Aquestive Therapeutics to be an opportunity to invest in proprietary PharmFilm technology being leveraged to develop a pipeline of 10 drugs and candidates and to provide an oral alternative in patients having difficulty swallowing pills or only having invasive options like injections.
11/19/18
JMPS
11/19/18
NO CHANGE
Target $31
JMPS
Outperform
Aquestive CRL for 'peripheral' program has no read-through, says JMP Securities
After the FDA issued a CRL for Aquestive Therapeutics' tadalafil oral film candidate, JMP Securities analyst Jason Butler said he did not have this "peripheral" product in his valuation for Aquestive shares and he does not believe it is a major focus for investors. The issues raised by FDA appear specific to this product and he does not see any negative read-through to the company's other programs, Butler tells investors. He maintains an Outperform rating and $31 price target on Aquestive shares.
RDY Dr. Reddy's
$36.89

0.41 (1.12%)

03/27/18
EVER
03/27/18
NO CHANGE
Target $155
EVER
Outperform
Evercore sees higher chances of Revlimid patent settlement for Celgene
Evercore ISI analyst Umer Raffat believes the odds of a Revlimid patent settlement between Celgene (CELG) and Dr. Reddy's (RDY) have gone up "considerably" following a recent court filing. The filing, according to the analyst, shows Dr. Reddy's agreed to resolve claims construction issues, which he believes "implies a clear alignment in thought process between both sides." A potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018, and could lead a quick re-rating in the valuation multiple, Raffat tells investors in a research note. He keeps Celgene as his top pick for 2018 with an Outperform rating and $155 price target.
05/29/18
RHCO
05/29/18
NO CHANGE
Target $96
RHCO
Hold
Celgene price target lowered to $96 from $106 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on Celgene (CELG) to $96 after last week's R&D meeting hosted by the management, which "highlighted" the importance of the multiple myeloma program to the company, its research into the mechanism of iMiD drugs, and its pursuit of anti-B-cell maturation antigen in treatment function. The analyst believes that while the company can sustain its position of leadership in myeloma, he is concerned with the overhang on the stock coming from intellectual property litigation on Revlimid, anticipating the stock to remain rangebound until next week's likely generic Revlimid settlement with Dr. Reddy's (RDY).

TODAY'S FREE FLY STORIES

TLND

Talend

$49.40

-1.81 (-3.53%)

09:36
03/25/19
03/25
09:36
03/25/19
09:36
Recommendations
Talend analyst commentary  »

Talend price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHI

Robert Half

$63.78

-2.58 (-3.89%)

09:36
03/25/19
03/25
09:36
03/25/19
09:36
Hot Stocks
Breaking Hot Stocks news story on Robert Half »

Robert Half mentioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:35
03/25/19
03/25
09:35
03/25/19
09:35
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
Lantheus promotes John Bolla to COO »

Lantheus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

MEOH

Methanex

$57.73

-2.64 (-4.37%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
M&G Investments announces four director nominees for Methanex board »

M&G Investments, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$41.28

0.75 (1.85%)

09:32
03/25/19
03/25
09:32
03/25/19
09:32
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton benefiting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:31
03/25/19
03/25
09:31
03/25/19
09:31
Hot Stocks
Lantheus announces upcoming retirement of Chief Medical Officer in September »

Lantheus Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

NEON

Neonode

$2.80

(0.00%)

09:28
03/25/19
03/25
09:28
03/25/19
09:28
Hot Stocks
Neonode says Convergence Promotions to act as sales and marketing partner »

Neonode announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.54

-0.525 (-8.66%)

09:27
03/25/19
03/25
09:27
03/25/19
09:27
Syndicate
Breaking Syndicate news story on PLx Pharma »

PLx Pharma files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$184.59

-6.555 (-3.43%)

09:26
03/25/19
03/25
09:26
03/25/19
09:26
Hot Stocks
Wex to acquire fuel card business of EG Group »

WEX announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IART

Integra LifeSciences

$55.29

-2.07 (-3.61%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
Integra LifeSciences participates in a conference call with JPMorgan »

Medical Supplies &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

, VRTX

Vertex

$181.49

-1.07 (-0.59%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Recommendations
Proteostasis, Vertex analyst commentary  »

Piper sees 'clear…

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

VRTX

Vertex

$181.49

-1.07 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 10

    Apr

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
A Spring Rebound for Producer Sentiment »

A Spring Rebound for…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a meeting »

Open Commission Meeting…

ORGS

Orgenesis

$5.01

-0.19 (-3.65%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Hot Stocks
Orgenesis to establish new facility for cell, gene therapy manufacturing »

Orgenesis announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVP

Avon Products

$3.06

0.28 (10.07%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Recommendations
Avon Products analyst commentary at DA Davidson »

Avon Products buyout…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSL

MidSouth Bancorp

$10.22

-0.49 (-4.58%)

09:23
03/25/19
03/25
09:23
03/25/19
09:23
Upgrade
MidSouth Bancorp rating change  »

Sandler O'Neill says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Conference/Events
JPMorgan retail analyst to hold an analyst/industry conference call »

Broadlines &…

PLAN

Anaplan

$38.98

-1.47 (-3.63%)

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Initiation
Anaplan initiated  »

Anaplan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDOR

Condor Hospitality Trust

$8.70

(0.00%)

09:19
03/25/19
03/25
09:19
03/25/19
09:19
Hot Stocks
Condor Hospitality Trust announces sale of non-core legacy hotel »

Condor Hospitality Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
03/25/19
03/25
09:18
03/25/19
09:18
Options
Overnight activity included 349 trades in SPX and 231 trades in VIX »

349 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTDR

Frontdoor

$32.78

0.38 (1.17%)

09:16
03/25/19
03/25
09:16
03/25/19
09:16
Initiation
Frontdoor initiated  »

Frontdoor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$79.94

-1.29 (-1.59%)

09:15
03/25/19
03/25
09:15
03/25/19
09:15
Downgrade
AbbVie rating change  »

AbbVie downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.